These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 17476932)
1. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers]. Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932 [TBL] [Abstract][Full Text] [Related]
2. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Abou-Khalil B; Hemdal P; Privitera MD Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078 [TBL] [Abstract][Full Text] [Related]
3. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573 [TBL] [Abstract][Full Text] [Related]
4. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168 [TBL] [Abstract][Full Text] [Related]
5. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754 [TBL] [Abstract][Full Text] [Related]
6. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
7. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy. Lee GH; Kim BM; Kang JK; Lee SA Seizure; 2013 Apr; 22(3):185-8. PubMed ID: 23280273 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy and Safety of Levetiracetam as an Add-on Therapy for Symptomatic Refractory Epilepsy Treated in a Department of Neurosurgery]. Suzuki K; Kawataki T; Sato H; Ogiwara M; Kinouchi H Brain Nerve; 2016 Dec; 68(12):1471-1476. PubMed ID: 27916757 [TBL] [Abstract][Full Text] [Related]
9. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Steinhoff BJ; Trinka E; Wieser HG; Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Ben-Menachem E; Gilland E Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Kanemura H; Sano F; Tando T; Sugita K; Aihara M Brain Dev; 2013 May; 35(5):386-91. PubMed ID: 22871391 [TBL] [Abstract][Full Text] [Related]
12. Levetiracetam monotherapy--outcomes from an epilepsy clinic. Stephen LJ; Kelly K; Parker P; Brodie MJ Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583 [TBL] [Abstract][Full Text] [Related]
13. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Giroux PC; Salas-Prato M; Théorêt Y; Carmant L Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014 [TBL] [Abstract][Full Text] [Related]
14. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Tanaka S; Tanaka T Epileptic Disord; 2013 Jun; 15(2):132-41. PubMed ID: 23774199 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Grosso S; Cordelli DM; Franzoni E; Coppola G; Capovilla G; Zamponi N; Verrotti A; Morgese G; Balestri P Seizure; 2007 Jun; 16(4):345-50. PubMed ID: 17368928 [TBL] [Abstract][Full Text] [Related]
16. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. Hirsch M; Hintz M; Specht A; Schulze-Bonhage A Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of levetiracetam use following resective surgery in patients with refractory epilepsy: a prospective observational study. Zeng TF; Li YH; An DM; Chen L; Lei D; Zhang B; Li JM; Zhou D Epilepsy Res; 2014 Dec; 108(10):1904-11. PubMed ID: 25454502 [TBL] [Abstract][Full Text] [Related]
18. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Kinirons P; McCarthy M; Doherty CP; Delanty N Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211 [TBL] [Abstract][Full Text] [Related]
19. [Experience with levetiracetam in childhood epilepsy]. Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712 [TBL] [Abstract][Full Text] [Related]
20. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]